Skip to content
DataLookout
Menu

EXUROCNCT07951060

LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and DNA Repair Deficiency

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Dose-Limiting Toxicity
Timeframe: During the first treatment cycle (21 days).
Recommended Phase II Dose (RP2D) of LP-184
Timeframe: During Phase Ib dose evaluation, up to approximately 6 months
Objective Response Rate (ORR) According to RECIST Version 1.1
Timeframe: From treatment initiation until disease progression or end of treatment, up to 1 year.

Secondary (3)

Progression-Free Survival (PFS)
Overall Survival (OS)
Duration of Response (DoR)

Arms and interventions

LP-184 armExperimental

All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. In Phase Ib, a modified 3+3 dose de-escalation design will be used to determine the recommended Phase II dose (RP2D). In Phase II, participants will receive LP-184 at the established RP2D.

Drugs: Intravenous infusion of LP-184 on Day 1 and Day 8 of a 21-day cycle.

Sites

1 site in 1 country

  • Rigshospitalet, Phase 1 Unit, Department of Oncology, Section 5073. Address: Blegdamsvej 9, 2100 Copenhagen, DenmarkCopenhagen, Denmark